Clinical trials in HNSCC patients are therefore evaluating the efficiency of PI3K/AKT/mTOR inhibitors, often using rapamycin analogs [81], and show partially promising treatment responses [84,85]. This evidence concerns the gene PIK3CA and head and neck squamous cell carcinoma.